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Abstract
Forkhead box M1 (FOXM1) is a proliferation-associated transcription factor essential for cell cycle progression. Numerous
studies have documented that FOXM1 has multiple functions in tumorigenesis and its elevated levels are frequently
associated with cancer progression. Here, we characterized the role of ERK/FOXM1 signaling in mediating the metastatic
potential of ovarian cancer cells. Immunohistochemical (IHC), immunoblotting and semi-quantitative RT-PCR analyses found
that both phospho-ERK and FOXM1 were frequently upregulated in ovarian cancers. Intriguingly, the overexpressed
phospho-ERK (p,0.001) and FOXM1 (p,0.001) were significantly correlated to high-grade ovarian tumors with aggressive
behavior such as metastasized lymph node (5 out of 6). Moreover, the expressions of phospho-ERK and FOXM1 had
significantly positive correlation (p,0.001). Functionally, ectopic expression of FOXM1B remarkably enhanced cell
migration/invasion, while FOXM1C not only increased cell proliferation but also promoted cell migration/invasion.
Conversely, inhibition of FOXM1 expression by either thiostrepton or U0126 could significantly impair FOXM1 mediated
oncogenic capacities. However, the down-regulation of FOXM1 by either thiostrepton or U0126 required the presence of
p53 in ovarian cancer cells. Collectively, our data suggest that over-expression of FOXM1 might stem from the constitutively
active ERK which confers the metastatic capabilities to ovarian cancer cells. The impairment of metastatic potential of cancer
cells by FOXM1 inhibitors underscores its therapeutic value in advanced ovarian tumors.
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Introduction
Ovarian cancer is one of the most lethal gynecologic
malignancies worldwide. Due to the non-specific symptoms, most
of ovarian cancer cases are presented with advanced stage disease
and associate with high mortality rate [1]. In the advanced ovarian
cancer, tumor cells are highly invasive and the subsequent cancer
metastasis leads to death [2]. Both cell migration and invasion
contribute the metastatic ability of the tumor cells and the genetic
mechanism that regulates metastasis remains largely unknown.
Therefore, it is of paramount importance to identify molecular
mediators conferring the metastatic potential to ovarian cancer
cells that may be used as tumor markers in predicting risk of
ovarian cancer progression.
Forkhead Box M1 (FOXM1) is a typical transcription factor that
belongs to the Forkhead Box family [3]. FOXM1 is well-known for
its critical role in cell cycle progression by regulating the G1/S and
G2/M phases of cell cycle transition and ensuring a proper
execution of mitotic cell division [3,4,5]. However, mounting
evidence supports a link between aberrant expression of FOXM1
and human carcinomas such as pancreatic cancer, basal cell
carcinomas, glioblastomas and cervical cancer [6,7,8,9]. More
importantly, the increased expression of FOXM1 has remarkable
correlation with the progressive stages of numerous human cancers
[6,9,10,11,12]. Hence, FOXM1 not only promotes tumorigenesis
by endowing proliferative capacity and leading to uncontrolled cell
division at theearly periodofcancer development butalso enhances
other tumorigenic behaviors in other stages of cancer development
[12,13,14]. To date, several lines of evidence have shown that
FOXM1 could enhance angiogenesis in glioma cells [15],
anchorage-independent growth ability in cervical cancer cells [6],
tumor growth ability of glioma cells [7] and metastasis of
hepatocellular carcinomas cells in nude mice [16], implying the
diverse roles of FOXM1 in tumorigenesis. Recently, the Cancer
Genome Atlas Research Network has used a probabilistic graphical
model (PARADIGM) to prove that FOXM1 signaling is critically
associated with serous ovarian cancer pathophysiology [17].
However, the expression status and functional roles of FOXM1 in
ovarian cancer, especially in cell migration/invasion are largely
speculative. This highlights an urgent need to delineate the
molecular mechanism underlying the cancer progression so as to
increase the survival rate of patients with ovarian cancer.
Constitutive activation of ERK signaling is usually linked with
neoplastic transformation such as uncontrolled cell growth by
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[18,19,20,21]. Previous studies have reported that ERK acts
upstream of FOXM1 and the phosphorylation of FOXM1 by
ERK are required for the nucleus translocation and subsequent
transactivation [22]. In addition, FOXM1 has been shown to be
one of the ERK effectors in human hepatocellular carcinoma and
breast cancer [23,24]. However, the function of ERK/FOXM1
signaling cascade in regulating cell migration/invasions has not yet
been clearly elucidated.
In this study, we firstly analyzed the expression status and
clinicopathological correlation of FOXM1 in ovarian cancer.
Several tumorigenic assays were conducted in ovarian cancer cell
models using gain- and loss-of function of FOXM1 through
enforced expression of FOXM1 or inhibition of endogenous
FOXM1 by thiostrepton or U0126. We also gave the data
showing the importance of p53 status in the use of FOXM1
inhibitors. Moreover, we provided the first in vitro evidence of
ERK/FOXM1 signaling cascade in promoting cell migration/
invasion in ovarian cancer cells. This confers an encouraging
target in combating advanced ovarian cancer.
Results
FOXM1 is over-expressed and correlates with pERK
expression and high-grade subtype of ovarian cancer
To study the significance of FOXM1 expression in ovarian
cancer development, IHC analysis on a commercial tissue array of
97 ovarian tissue samples, including 2 normal, 2 benign, 1
borderline cystademoma and 96 malignant tumor samples was
conducted. High FOXM1 expression was significantly correlated
with high-grade tumors (Grade 3) (P,0.001), in which 73.33% of
Grade 3 tumors cases exhibited over-expression of FOXM1
whereas 68% of Grades 1 and 2 tumors cases showed low
expression of FOXM1 (Table 1). Regarding the tumor subtype,
the expression of FOXM1 was highly correlated with endometriod
adenocarcinoma (P,0.05), in which 74.07% of cases demonstrat-
ed over-expression of FOXM1 (Table 1). Additionally, 5 out of 6
cases with lymph node metastasis showed over-expression of
FOXM1 (data not shown). Despite the limited sample size, it could
be a reference for an association between FOXM1 and distant
metastasis. Besides, a remarkable correlation was detected between
the up-regulation of both FOXM1 and pERK (P,0.001) (Table 1).
Similar to FOXM1, a significant correlation was detected between
the expression of pERK and high-grade tumors (P,0.001), in
which 66.67% of Grade 3 tumors showed high expression of
pERK (Table 2). Concordant weak to very strong staining of
pERK and FOXM1 were also observed from borderline
cystademoma to Grade 3 tumor, implicating the importance of
the two proteins in tumor progression of ovarian cancer (Fig. 1A).
For the cell lines study, the expressions of pERK and FOXM1
also demonstrated a good correlation in a panel of ovarian cancer
and HOSEs cell lines. Both proteins were highly expressed in
cancerous cell lines, especially in OVCAR3, SKOV3, OVCA429
and A2780cp, whereas they showed lower expressions in HOSE
cell lines (Fig. 1B). Similarly, real time QPCR analysis using
specific primers according to previous report [12] revealed that
both FOXM1B (27 to 250-fold) and FOXM1C (25 to 172-fold) were
up-regulated in ovarian cancer cell lines as compared with HOSE
cell lines (Fig.1C). This result was consistent to the findings of
western blot analysis and also showed that there was no difference
of the expression patterns between two isoforms in ovarian cancer
cells. Collectively, these data suggest that both ERK activity and
FOXM1 expression are up-regulated and positively correlated in
ovarian cancers, especially in aggressive high-grade tumors, which
implicates sharing of a common pathway in ovarian cancer
progression.
FOXM1 promotes cell proliferation and cell migration/
invasion
Given that high-grade tumors were highly proliferative and
metastatic, we reasoned that FOXM1 plays a certain role in
regulating cell motility and invasion. To probe the oncogenic roles
of FOXM1 in ovarian cancer, we assessed the functional effects of
two active FOXM1 isoforms, FOXM1B and FOXM1C, on
A2780cp and OVCA433 cells (Fig. 2A). Consistent with previous
reports [14,25], FOXM1C could increase the cell proliferation
capacity in A2780cp (P,0.005) and OVCA433 (P=0.006)
ovarian cancer cells, while FOXM1B just showed slight increased
effect (Fig. 2A). On the other hand, ectopic expression of
FOXM1B and FOXM1C could promote faster wound closure
in A2780cp and OVCA433 ovarian cancer cells by wound healing
assay (Fig. 2B). By transwell migration/invasion assays, introduc-
tion of FOXM1B and FOXM1C also showed a significant
increased cell migration (P,0.05 in A2780cp and P,0.005 in
OVCA433) (Fig. 2C) and cell invasion (P,0.05 in A2780cp and
P,0.01 in OVCA433) (Fig. 2D) abilities in A2780cp and
OVCA433 cells compared with the vector controls. Interestingly,
FOXM1B had relatively stronger influence in promoting cell
migration and invasion as compared with FOXM1C. Taken
together, these data confer that FOXM1 isoforms could
differentially promote cell proliferation, migration/invasion in
ovarian cancer cells.
Effective inhibition of FOXM1 expression by thiostrepton
requires p53
The thiazole antibiotic thiostrepton can specifically inhibit the
expression of FOXM1 at gene promoter level in breast cancer cell
lines [26], and therefore it was used to deplete the expression of
FOXM1 in ovarian cancer cells. Upon thiostrepton treatment, we
observed different responses of FOXM1 in ovarian cancer cell
lines carrying different p53 genotypic statuses: OVCA433 (p53
wild-type), A2780cp (p53 mutant) and SKOV3 (p53 deleted).
OVCA433 and A2780cp cells showed a pronounced drop of
FOXM1 expression in a time- and dosage-dependent manner, as
well as an increased expression of p53 at higher dose (20 mM) of
thiostrepton (Fig. 3A). On the other hand, SKOV3 was resistant to
thiostrepton and FOXM1 expression sustained at 10, 30 and
50 mM. These findings suggest that p53 might be involved in the
thiostrepton acting mechanism. Considering the very opposite
roles of p53 and FOXM1 in cell cycle regulation and the negative
impact of p53 on FOXM1 expression shown in previous micro-
array result [5,27,28,29,30], we assessed the expression of
FOXM1 upon alteration of p53 expression in ovarian cancer
cells. Transient transfection of p53 remarkably reduced FOXM1
not only in protein level (Fig. 3B) but also in mRNA level (Fig. 3C)
in OVCA433, A2780cp and SKOV3. These results indicate that
p53 negatively regulates both mRNA and protein levels of
FOXM1 and p53 is essential for thiostrepton to exert the
inhibition on FOXM1 expression in ovarian cancer cells.
Down-regulation of FOXM1 impairs cell migration/
invasion
We hypothesized that thiostrepton can repress the ovarian
cancer cell migration/invasion by inhibiting the expression of
FOXM1. Since thiostrepton could induce apoptotic effect on
cancer cells [26], XTT assays were performed thrice to exclude
the factor of reduced cell viability which may affect the accuracy of
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the cell viability of the above cell lines showed no significant
changes upon treatment of the dosage range of 0 to 10 mM
thiostrepton (Fig. S1). Upon treatment with thiostrepton,
OVCA433 cells showed an obvious repression of cell migration,
with ,50% decrease of wound closure rate as compared with the
untreated control in wound healing assay (P,0.05) (Fig. 4A).
Similar inhibitory effect on cell migration was observed in
A2780cp cells (data not shown). However, treatment on SKOV3
showed no significant influence on cell migratory inhibition (Fig.
S2). Furthermore, treatment of 10 mM thiostrepton on OVCA433
also dramatically reduced approximately 37% cell migration
(P,0.05), and 75% cell invasion (P,0.05) abilities as compared
with controls in Matrigel assay (Fig. 4B). Taken together, these
data suggest that FOXM1 significantly regulates cell proliferation
and cell migration/invasion in ovarian cancer cells.
ERK activity regulates cell migration mediated by FOXM1
in ovarian cancer cells
As the above study implied the plausible association of ERK
activity and FOXM1 expression (Fig. 1A and 1B), it is interesting
to investigate the underlying molecular mechanism. OVCA433
and OV2008 cells were treated with the MEK inhibitor U0126
and the levels of pERK and FOXM1 were evaluated at different
time points by western blot analysis. A remarkable decrease of
pERK level was observed in both cell lines as early as 30 minutes
and there was a concomitant reduction of FOXM1 expression
(Fig. 4C). Besides, the inhibition of FOXM1 expression sustained
as long as the ERK activity remained suppressed (Fig. 4C). Since
ERK lies up-stream of FOXM1 [23,24], we reasoned that
inhibition of ERK activity should abrogate cell migration of
ovarian cancer cells through down-regulating FOXM1. Indeed,
using wound healing assay, OVCA433 cells treated with U0126
showed a significant increase of wound closure time (2-fold more)
compared with the control (P,0.05) (Fig. 4D). On the other hand,
there was no reduction of FOXM1 expression and cell motility in
SKOV3 cells (p53 deleted) upon treatment of U0126 (Fig. S3),
indicating that the presence of p53 is required for U0126 or
thiostrepton mediated FOXM1 inhibition. Taken together, these
findings support an essential role of FOXM1 in mediating the
effect of ERK on cell migration in ovarian cancer cells.
MMP-9 and uPAR are FOXM1 downstream targets
regulating cell migration/invasion
Extracellular proteases like metalloprotease-9 (MMP-9) and
urokinase receptor (uPAR) are markers to the acquisition of the
metastatic capability [2]. Hence, we examined the levels of MMP-
9 and uPAR to confirm the effect of FOXM1 on cell motility and
invasion. By suppressing FOXM1 expression with 5 and 10 mM
thiostrepton in OVCA433, the levels of both MMP-9 and uPAR
were reduced by about 20 to 30% (Fig. 5). Conversely, transient
over-expression of FOXM1 increased MMP-9 and uPAR levels by
,1.7-fold and ,2.4-fold, respectively (Fig. 5). These data suggest
that FOXM1 regulates the cell migration/invasion through
transcriptionally up-regulating the expressions of MMP-9 and
uPAR.
Discussion
In this study, we have showed that FOXM1 was aberrantly up-
regulated in ovarian cancer, particularly in high-grade sub-type.
Similarly, increased phospho-ERK in concomitant with FOXM1
was significantly associated with high-grade ovarian cancer. We
thus proposed that FOXM1 overexpression might stem from
constitutively activated ERK signaling that contributes to the
metastatic capability in cancer cells. Our study indicates that the
ERK/FOXM1 signaling cascade may be a promising target for
therapeutic intervention in ovarian cancer.
We and other groups have previously reported that FOXM1 is
frequently deregulated in a variety of human cancers [31].
Importantly, the increased FOXM1 expression was associated
with the tumor progression of human cancers [6,9,10,11,12].
However, the functional roles of FOXM1 in ovarian cancer
remain largely unexplored. Here, we showed that both mRNA
and protein levels of FOXM1 were up-regulated in ovarian cancer
tissues and cell lines. FOXM1 overexpression was significantly
correlated with high-grade ovarian tumors, indicating that
FOXM1 may play an oncogenic role in ovarian cancer, especially
in the high-grade subtype. We therefore explored the effect of
FOXM1 in cell migration/invasion which is a common tumor-
igenic scenario observed in aggressive high-grade tumors.
Table 1. Clinical-pathological analysis of FOXM1expression.
FOXM1 expression
Parameters n(=96) #150 .150 p
Grade
1 and 2 50 34 (68%) 16 (32%)
3 45 12 (26.67%) 33 (73.33%) ,0.001*
Stage
Early 48 24 (50%) 24 (50%)
Late 48 22 (45.83%) 26 (54.17%) 1
Subtypes
Endometriod
Adenocarcinoma
27 7 (25.93%) 20 (74.07%)
Others 69 42 (60.87%) 27 (39.13%) 0.003*
Musinous
Cystadenocarcinoma
21 13 (61.9%) 8 (38.1%)
Others 75 35 (46.67%) 40 (53.33%) 0.324
Serous Cystadenocarcinoma49 28 (57.14%) 21 (42.86%)
Others 47 21 (44.68%) 26 (55.32%) 0.307
pERK
Low Expression 67 46 (68.66%) 21 (31.34%)
High Expression 34 7 (20.59%) 27 (79.41) ,0.001*
doi:10.1371/journal.pone.0023790.t001
Table 2. Clinical-pathological analysis of phospho-ERK
expression.
pERK expression
Parameters n (=96) #150 .150 p
Grade
1 and 2 51 46 (90.2%) 5 (9.8%)
3 45 15 (33.33%) 30 (66.67%) ,0.001*
Stage
Early 47 31 (66%) 16 (34%)
Late 49 29 (59.18%) 20 (40.82%) 0.675
doi:10.1371/journal.pone.0023790.t002
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FOXM1B and FOXM1C are shown to be elevated in numerous
human cancers. Particularly, FOXM1B was demonstrated to
promote angiogenesis, tumor growth of glioma cells and metastasis
of HCC in the absence of Arf while FOXM1C was found to
enhance cell growth and anchorage-independent ability of cervical
cancer cells [6,7,15,16]. Here, enforced expression of either
FOXM1B or FOXM1C could promote cell proliferation,
migration and invasion in ovarian cancer cells. Although our
findings showed that FOXM1C preferably increased cell prolif-
eration while FOXM1B promoted cell migration/invasion, the
simultaneous reduction of both FOXM1 isoforms using thios-
trepton led to corresponding effects in both cell proliferation as
well as cell migration/invasion. The effect of FOXM1 was further
confirmed by examining the expressions of known markers in cell
migration/invasion, MMP-9 and uPAR, which are in line with the
metastatic role of FOXM1 reported in other human cancers
[9,16,32,33]. Whether FOXM1 directly regulate these markers or
other downstream effectors requires further investigation. Never-
theless, all of these observations suggest that the aberrant up-
regulation of FOXM1 attributes the tumorigenic properties in
high-grade ovarian cancer.
ERK is one of a crucial mediator in Raf/ERK/MAPK
signaling axis maintaining diverse cellular function including cell
proliferation, apoptosis as well as migration [34]. Previously, ERK
has been shown to be constitutively active in ovarian cancer and
our identification of high expression level of pERK in histological
high-grade ovarian cancer and cell lines indicates its crucial role in
Figure 1. FOXM1 and pERK are over-expressed in high-grade ovarian tumor and correlate to each other in ovarian tumors and
cancer cell lines. (A) Representative IHC showed the immunoreactivities of FOXM1 and pERK in borderline, Grade 1, Grade 2 and Grade 3 tumor on
a ovarian cancer tissue array (OVC1021) (x20). Increasing staining of both FOXM1 and pERK was observed along with the progression of cancer which
implicates their potential roles in tumorigenesis. (B) Western blotting showed the expressions of pERK, ERK and FOXM1 in HOSEs and ovarian cancer
cell lines. (C) Real time QPCR analysis revealed the expressions of FOXM1 isoforms; FOXM1B and FOXM1C in HOSEs and ovarian cancer cell lines.
FOXM1A was neglected in this experiment because it was reported as being transcriptionally inactive.
doi:10.1371/journal.pone.0023790.g001
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pERK and FOXM1 levels were tightly correlated during cancer
progression, especially in high-grade ovarian cancer. We specu-
lated that elevated FOXM1 expression is triggered by the
constitutive activation of ERK, which leads to enhanced cell
motility in ovarian cancer. As expected, their relationship was
confirmed by manipulating the activity of ERK, which resulted in
parallel changes of FOXM1 expression. In another study, motifs
resembling the ERK target sequence have been found in FOXM1
and activation of ERK activity was demonstrated to induce the
transactivating ability of FOXM1C [22]. Thus, suppressing ERK
activity by U0126 would reduce FOXM1 phosphorylation which
finally leads to inhibition of FOXM1 expression by disrupting its
own positive feedback loop [36]. Though it gave us a clue that the
transactivation of FOXM1 depends on phosphorylation by ERK
at the post-transcriptional level, there is lack of reports regarding
the functional attributes of activated ERK/FOXM1 signaling axis
in ovarian cancer. In the wound healing study, in fact, the decrease
in wound closure rate due to inhibited ERK activity and the
reduction of FOXM1 expression upon U0126 treatment strongly
suggests that FOXM is one of the major downstream effectors of
ERK signaling. Moreover, thiostrepton and U0126 suppressed cell
migration to a similar extent (40% as compared to 50%). Taken
together, we believe that up-regulated ERK activity and the
subsequent increase of FOXM1 expression contribute further
induction of oncogenic behaviors, supporting that ERK/FOXM1
signaling axis facilitates cell migration in ovarian cancer.
Previous studies have demonstrated the promising effect of
thiostrepton in impairing the tumorigenic behaviors mediated by
FOXM1 [26,37,38]. Given the differential sensitivity of FOXM1
to down-regulation by thiostrepton treatment in cell lines with
various status of p53, it is tempting to speculate the importance of
p53 for the action of thiostrepton. Based on the fact that loss of
p53 function is a common event in tumors and FOXM1 is
negatively regulated by p53, we speculated that losing p53
expression may cause the deregulation of FOXM1 and thereby
Figure 3. p53 is essential for the thiostrepton-mediated down-regulation of FOXM1. (A) Western blotting revealed the down-regulation of
FOXM1 and up-regulation of p53 in ovarian cancer cell lines; OVCA433 and A2780cp, but not in SKOV3 upon treatment of thiostrepton under various
dosages and time intervals. (B) Western blotting showed that transient transfection with p53 could suppress FOXM1 expression in ovarian cancer cells
(OVCA433, A2780cp and SKOV3). (C) Real time PCR indicated down-regulation of FOXM1 transcripts upon the transient transfection of p53.
doi:10.1371/journal.pone.0023790.g003
Figure 2. Up-regulation of FOXM1B or FOXM1C isoforms induces cell proliferation, migration and cell invasion in ovarian cancer
cells. (A) XTT cell proliferation assay demonstrated that FOXM1C could remarkably increase cell proliferation of in A2780cp (*P,0.005) and OVCA433
(**P=0.006) ovarian cancer cells, while FOXM1B just had slightly effect. Western blotting showed the expressions of FOXM1B (1B) and FOXM1C (1C)
in A2780cp and OVCA433 cells by using anti-FOXM1 (K19). The empty vector was used as negative control (V). (B) Wound healing assay showed faster
wound closure rate of FOXM1B or FOXM1C ectopic expressing A2780cp (*P,0.05) and OVCA433 (**P,0.01) cells as compared with vector control
(*P,0.05). (C) Transwell migration assay and the bar chart showed higher migratory rate in FOXM1B and FOXM1C ectopic expressing cells of A2780cp
(*P,0.05) and OVCA433 (*P,0.005) as compared with their vector controls (V). (D) Transwell cell invasion assay and the bar chart showed higher
invasion rate through Matrigel-coated membrane in FOXM1B and FOXM1C ectopic expressing cells of A2780cp (*P,0.05) and OVCA433 (*P,0.01) as
compared with their vector controls (V). The above experiments were performed thrice independently and the result was plotted.
doi:10.1371/journal.pone.0023790.g002
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cell line SKOV3 showed no response of FOXM1 to various doses
of thiostrepton as well as MEK inhibitor, U0126, while FOXM1
could be easily suppressed at multiple doses in OVCA433 and
A2780cp which carry wild type and mutated p53 genes
respectively. Previous studies showed that thiostrepton may elicit
apoptotic effect on cancer cells by stabilizing p53 expression [39]
and the up-regulation of p53 at higher dosage may further assist
the suppression of FOXM1. Interestingly, thiostrepton or U0126
had no influence on SKOV3 carrying deleted p53 gene, whereas
ectopic expression of p53 abolished the expression of FOXM1 at
both RNA and protein level, consistent with other studies [28,30].
This uncovers the requisite role of p53 in mediating the
suppressive effect of thiostrepton on FOXM1 expression. Apart
from impairing the cell migration/invasion ability, another group
also showed that the use of thiostrepton could also increase
apoptosis and proliferative arrest in human cancer cells which
further underscores the therapeutic value of thiostrepton
[26,37,38,39,40]. Collectively, our study supports that thiostrepton
functions by suppressing FOXM1 expression via p53 to subse-
quently alleviate the tumorigenicity and up-regulating p53 to
induce cell death.
In conclusion, our study revealed a link between ERK/FOXM1
signaling axis and the metastatic behavior of ovarian cancer cells.
Moreover, we uncovered a critical role of p53 in mediating the
action of thiostrepton. Hence, both U0126 and thiostrepton
represent promising starting points to establish anti-cancer therapy
in ovarian cancer through the repression of FOXM1.
Materials and Methods
Cell lines and cell culture
Five immortalized human ovarian surface epithelial cells were
used: HOSE10-2, HOSE11-12, HOSE17-1, HOSE20-3 and
HOSE21-3 (from Professor George Tsao, The University of Hong
Kong). Nine ovarian cancer cell lines were used: A2780s A2780cp,
OV2008, C13* (from Professor Benjamin Tsang, The University
of Ottawa), OV420, OV429, OV433, OVCAR3 and SKOV3
(American Type Culture Collection, Rockville). All cell lines were
incubated at 37uCi n5 %C O 2 in either minimum essential
Figure 4. ERK activity requires FOXM1in regulating cell migration of ovarian cancer cells. (A) Wound healing assay showed lower wound
closure rate of thiostrepton-treated OVCA433 cells as compared with untreated control (*P,0.05). (B) Transwell migration assay and the bar chart
showed significantly lower number of migratory cells through Matrigel-coated membrane in FOXM1-depleted OVCA433 cells than the control
(*P,0.05) (upper). Transwell cell invasion assay and the bar chart showed lower invasion rate in FOXM1-depleted OVCA433 cells following
thiostrepton treatment when compared with the control (*P,0.05) (lower). (C) Western blotting revealed the down-regulation of FOXM1 in ovarian
cancer cell lines (OVCA433 and OV2008) upon treatment with U0126 for various time intervals. (D) Wound healing assay demonstrated lower wound
closure rate of U0126-treated OVCA433 cells as compared with untreated control (*P,0.05). Three independent experiments were performed and the
result was plotted.
doi:10.1371/journal.pone.0023790.g004
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Gaithersburg) with 10% fetal bovine serum (Gibco) and 1%
Penicillin-Streptomycin (Gibco).
Plasmids and transfection
The lentiviral pCDH-FOXM1B and pCDH-FOXM1C plas-
mids were generated by subcloning FOXM1B and FOXM1C
cDNAs from pcDNA3-FOXM1B and pcDNA3-FOXM1C plas-
mids into pCDH-MSCV-MCS-EF1-GFP-Puro lentiviral plasmid
(SBI, Mountain View, CA) respectively. The pRcCMV-p53
plasmid was from Prof. Randy YC Poon (Section of Biochemistry
and Cell Biology, Hong Kong University of Science and
Technology, Hong Kong). LipofectAMINE
TM 2000 transfection
reagent (Invitrogen Life Technologies, Carlsbad, CA) was used for
cell transfection according to the manufacturers’ instruction. The
pCDH-MSCV-MCS-EF1-GFP-Puro and pcDNA3.0 empty vec-
tors were used as negative controls. To establish FOXM1B and
FOXM1C stably expressing cells, lentiviral infected cells were
selected by 2 mg/ml Puromycin (Sigma) for 2 weeks and verified
by western blot analysis.
Semi-quantitative (SQ-PCR) and Quantitative (QPCR)
reverse transcriptase-polymerase chain reaction
Total RNA was isolated by TRIzol (Invitrogen) according to the
manufacturer’s protocol. Complementary DNA was synthesized
using reverse transcription reagent kit (Applied Biosystems, Foster
City). Subsequently, cDNA was used to perform PCR using
specific genes primers of FOXM1B (forward, 59-TTGCCCC-
CAAGGTGCTGCTA-39 and reverse, 59- GGAGATTGGGAC-
GAATCCTC-39), FOXM1C (forward, 59-CACCCATCAC-
CAGCTTGTTT39 and reverse, 59-GGAGATTGGGACGAA-
TCCTC-39), MMP9 (forward, 59- CATCGTCATCCAGTT-
TGGTG and reverse, 59-GCCTTGGAAGATGAATGGAA-39)
and uPAR (forward, 59-GCCTTACCGAGGTTGTGTGT-39 and
reverse, 59- GGCAGATTTTCAAGCTCCAG -39) under the
condition of 94uC (5 min), followed by 30–35 cycles of 95uC
(30 sec), 57uC (30 sec) and 72uC (30 sec), then finally 72uC
(10 min) and 4uC. The relative amount of gene was normalized
against GAPDH mRNA.
Q-PCR was performed by TaqManH Gene Expression Assays
and SYBR Green Gene Expression Assay. To validate the
expression of FOXM1 isoforms, specific primers targeting against
FOXM1B and FOXM1C were designed according to Kalin et al
[11] and purchased from Applied Biosystems. To examine the
expression of p53, specific TaqMan probes (Applied Biosystems)
included in PCR mix were subjected to PCR under the condition
of 95uC for 2 minutes, 40uC cycles at 95uC for 15 seconds and
60uC for 1 minute. Relative amount of RNA in each sample was
determined by comparative CT method with the 7500 System
SDS software (version 1.3.1), from which the fold difference was
compared to the internal control 18S and TBP and the relative fold
difference was then normalized to the calibrator. The relative
expression level of target gene was interpreted as the fold
difference to the endogenous control.
Western blotting and immunohistochemical (IHC)
analyses
Total protein was prepared by adding suitable amount of 1x
lysis buffer to the cell pellet. Protein samples were separated by
SDS-PAGE according to the standard western blot procedures
and then electroblotted to the Hybond-P membranes (Amersham
Pharmacia Biotech, Cleveland) followed by blocking with 5% skim
milk for 30 minutes. The blots were incubated with primary
monoclonal antibodies; anti-ERK, anti-pERK (Cell Signaling
Technology), anti-FOXM1 (K-19), anti-p53 (Sigma Chemical Co.,
St. Louis, MO) and anti-b-actin (Sigma-Aldrich, MO) overnight at
4uC. Anti-mouse or anti-rabbit secondary antibody conjugated to
horse radish peroxide (Amersham Pharmacia Biotech, OH) was
used and the signal was then visualized by enhanced chemilumi-
nescence (Amersham).
For immunohistochemical analysis, formalin-fixed paraffin-
embedded ovarian cancer tissue array (OVC1021) (Pantomics
Inc, San Francisco, CA) was immuno-stained with primary
monoclonal anti-FOXM1 (C-20, Santa Cruz) or pERK (Cell
Signaling Technology) in 1:50 dilution. All of the stained tissue
sections were identified as either positive or negative. For those
positive immuno-reactive samples, the staining was scored in terms
of proportion of stained area (0–100%) and intensity (+1, faint; +2,
Figure 5. FOXM1 regulates the cell migration/invasion through up-regulation of MMP-9 and uPAR expressions. Semi-quantitative RT-
PCR showed that inhibition of FOXM1 expression by thiostrepton (5 and 10 mM) in OVCA433 caused a decrease of MMP-9 and uPAR expressions (left),
whereas transiently transfection with FOXM1 expression plasmid (1 and 2 mg) in OVCA433 showed an increase of MMP-9 and uPAR expression (right).
The numerical value under each panel referred to the mRNA expression level relative to the control.
doi:10.1371/journal.pone.0023790.g005
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was determined by multiplying the percentage of stained area and
intensity. All tissue section was examined and scored by two
investigators.
Cell viability assay
Cell proliferation kit (XTT) (Roche) was used to measured cell
viability in the time course of 4 days according to the
manufacture’s manual. Three independent experiments were
performed in triplicate.
Wound healing assay
For wound healing assay, cells were seeded to full confluence in
a monolayer in a six-well plate. A micro-pipette tip was used to
scratch a single wound in each well. The plate was incubated at
5% CO2 at 37uC. Images were taken at 0, 12 and 24 hours after
scratching and were subsequently analyzed. The average cell
migration rate was expressed as relative width of wound/time.
Three independent experiments were carried out in duplicate.
Cell migration assay
For quantifying the cell migration ability using colorimetric cell
migration assay, a cell suspension containing 1.5610
5 cells in
serum free medium was added to each insert (Chemicon
International) while 500 ml serum-containing medium as a
chemo-attractant was added to the lower chamber (for FOXM1
inhibition test, 10 mM of thiostrepton was added included). The
plate was incubated for 12 hours at 37uCa t5 %C O 2 allowing the
cells to pass through the pores in the membrane. Afterwards,
remaining cell suspension was removed and the inserts were
stained with Cell Stain. Three independent sections in each
transwell filter were visualized under the microscope (TE300,
Nikon) and the number of cells was counted. The experiments
were performed thrice.
Cell invasion assay
BD BioCoat
TM Matrigel
TM Invasion Chamber (BD Bioscience)
was used to study the cell invasion. Inserts and wells were
rehydrated before the start of experiment. Cell suspension of
5610
5 cells in serum free medium was added to each insert while
500 ml serum-containing medium as a chemo-attractant was
added to the lower chamber (for FOXM1 inhibition test, 10 mM
of thiostrepton was added to both serum free and serum
containing medium). The plate was incubated for 36–48 hours
at 37uCa t5 %C O 2 allowing the cells to pass through the pores on
the membrane. Afterwards, remaining cell suspension was
removed and the inserts were stained with 500 ml of Crystal
Violet. Three independent sections in each transwell filter were
visualized under the microscope (TE300, Nikon) and the number
of cells was counted. The experiments were performed thrice.
Data analysis
Student’s t test was applied to analyze parametric data while
Mann-Whitney test was used for non-parametric data. Pearson
Chi-Square test was applied to examine the correlation between
FOXM1 and clinical parameters. A P-value less than 0.05 was
considered as significant in all tests. All data were expressed as
mean 6 SD.
Supporting Information
Figure S1 XTT assay showed that no significant change
in the cell proliferation rate of OVCA433 by treatment of
thiostrepton in a lower dose (5 and 10 mM) within 3 days.
(TIF)
Figure S2 Wound healing assay showed no influence in
cell migration of SKOV3 upon treatment with 5 mM and
10 mM of thiostrepton for 12–24 hrs when compared to
untreated control.
(TIF)
Figure S3 (Upper) Western blot analysis showed that no
change in FOXM1 expression in SKOV3 upon treatment
of 10 mM U0126 for 4 to 8 Hrs. (Lower) Wound healing assay
demonstrated that no change in cell migration of SKOV3 upon
treatment with 10 mM U0126 for 12–24 hrs when compared to
untreated control.
(TIF)
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